Fundamental Analysis (Long term)

18 Mar 2025 04:37

DISCLAIMER: NO BUY/SELL recommendation.

If you found this useful Share this Channel With your friends

Looking for more quality stock market insights?
Then MUST JOIN 👇
/channel/+Rn8RmYm0XMZTagXs

Fundamental Analysis (Long term)

18 Mar 2025 04:28

11 | Key Risks & Challenges

⚠️Regulatory Compliance Risks – Continuous adherence to global regulatory norms (USFDA, EU, WHO-GMP) is critical for CDMO & export growth.
⚠️Pricing Pressure & Competition – Intense competition in CDMO & generic markets may put pressure on margins.
⚠️Valuation & Profitability Risk – High P/E ratio (34.9) & ROE (17.0%) below ideal (20%) may affect investor sentiment.
⚠️Debt & Leverage Risk – D/E ratio at 0.29 is well-managed but expansion-driven investments must be monitored.
⚠️Global Economic Conditions – Slowdowns in regulated & emerging markets could impact international revenue growth.

📌 Innova Captab’s strong CDMO contracts, government incentives, and expanding global presence help mitigate these risks, ensuring long-term growth potential.

Fundamental Analysis (Long term)

18 Mar 2025 04:21

8 | Management Guidance & Future Plans

📌 Order Book & Key Growth Drivers
🔹Strong CDMO pipeline – 55% of revenue from contract manufacturing.
🔹New product launches – Focus on injectables, BFS, and complex formulations.
🔹 API backward integration – Strengthening cost efficiency via Sharon Bio-Medicine.
🔹₹450+ Cr CapEx – Investments in manufacturing, R&D, and global expansion.
🔹Regulated Market Growth – Increased filings & approvals in UK & Canada.

Must JOIN for such detail Analysis 👇
/channel/+Rn8RmYm0XMZTagXs

📊 Financial & Business Growth Guidance:
🔹FY25 revenue target: ₹1,250-₹1,300 Cr.
🔹FY26 revenue target: ₹1,500-₹1,600 Cr.
🔹CDMO Business Expansion – Expected to grow significantly in FY26.
🔹EBITDA Margin Target – Aiming for 16-18% range in FY26.

📈 Capacity Utilization & Expansion Plans:
🔹Jammu plant utilization – Expected to reach 75% in FY26, 100% by FY27.
🔹Increased production of injectables, LVP & BFS – Scaling output for domestic & export markets.
🔹New R&D facility (Panchkula) – Focus on complex formulations & international filings.

🚀 CDMO & Global Market Expansion:
🔹Secured multiple new CDMO contracts in regulated & semi-regulated markets.
🔹Expanding in UK & Canada – Targeting higher-margin specialty generics.

📑 Execution & Regulatory Readiness:
🔹₹500+ Cr worth of orders to be completed in next 6-9 months.
🔹Accelerated product filings – 131 new registrations planned across geographies.
🔹Regulatory compliance & audits – Strengthening readiness for global approvals.

📌 Innova Captab is set for rapid growth with strong CDMO contracts, capacity expansion, international market penetration, and innovation-driven R&D initiatives.

Fundamental Analysis (Long term)

18 Mar 2025 04:16

6 | Competitive Landscape, Market Positioning & Key Strengths

🌍 Industry Ranking & Competitors:
🔹Among the Top 3 Largest Finished Tablet & Capsule Manufacturers in India.
🔹Competing with Lupin, Sun Pharma, and Dr. Reddy’s in the CDMO & generics space.
🔹Aurobindo Pharma – Strong presence in regulated markets with a vast ANDA portfolio.
🔹Dr. Reddy’s – Leading CDMO player with strategic partnerships in high-growth markets.

📈 Market Positioning & Growth Strategy:
🔹CDMO Business Expansion – 55% of total revenue from CDMO; manufacturing 2,900+ CDMO products.
🔹Pipeline Growth – Investing in new formulations, injectables, and BFS products.
🔹International Expansion – Strengthening footprint in UK & Canada with increased filings & approvals.
🔹Emerging Market Strategy – Expanding distribution in Africa, CIS, and Southeast Asia.
🔹Jammu Facility Commercialization – Expected to drive ₹400-500 Cr incremental revenue in FY26.

🚀 Export Market Expansion:
🔹Growing exports to 25+ countries, targeting regulated markets (UK, Canada) & emerging markets.
🔹Dedicated regulatory teams for accelerating product approvals & market penetration.
🔹9M FY25 International Revenue Growth – ₹113 Cr revenue (17% YoY growth).

💡 Key Strengths of Innova Captab:
1️⃣ Diversified Product Portfolio – CDMO, branded generics, APIs, and injectables.
2️⃣ Long-Term Client Relationships – 80%+ clients associated for 5+ years.
3️⃣ Strong Presence in India & International Markets – Expanding in Tier 2 & Tier 3 cities domestically.
4️⃣ Robust R&D Capabilities – Panchkula R&D center to drive complex & specialty formulation development.
5️⃣ Advanced Manufacturing Facilities - 9 production blocks across Baddi, Jammu, and Sharon Bio-Medicine (API & Formulations).
6️⃣ Cost Efficiency & Government Incentives - GST-linked incentive (300% of investment in plant & machinery) & 6% capital interest subvention for Jammu facility.

📌 Innova Captab is solidifying its position as a top-tier CDMO and generics manufacturer, leveraging international expansion, product innovation, and strategic partnerships for sustained growth.

Fundamental Analysis (Long term)

18 Mar 2025 04:16

4 | Expansion & Growth Strategy

🏭Current Manufacturing Facilities & Installed Capacity:
1️⃣ Baddi, Himachal Pradesh (3 Production Blocks) – Tablets: 8.2B | Capsules: 2.4B | Ointments: 23M | Dry Powder Injectables: 60M | Dry Syrups: 54M | Liquid Orals: 71M
2️⃣ Jammu, India (Newly Commercialized - 4 Production Blocks) – Tablets: 10.6B | Capsules: 1.4B | Dry Powder Injectables: 547M | Dry Syrups: 311M | BFS (LVP & Respules): 562M
3️⃣ Sharon Bio-Medicine (Dehradun & Taloja - API & Formulations) – Tablets & Capsules: 2.01B | API Production: 313 MT

🚀 Planned Expansion & Growth Initiatives:
🔹Jammu Facility Ramp Up - ₹400-500 Cr incremental revenue expected in FY26, with a focus on dry powder injectables, LVP (Large Volume Parenterals), and respules.
🔹Panchkula R&D Center (Upcoming) – Dedicated research facility to develop generic & complex formulations; expected to enhance CDMO and international product pipeline.
🔹CDMO Business Growth – Increasing wallet share with existing clients while onboarding new clients for complex formulations.
🔹API & Formulation Expansion – Backward integration via Sharon Bio-Medicine to enhance cost efficiency and supply chain control.
🔹International Market Expansion – Strengthening presence in UK & Canada through increased filings and new approvals.
🔹Domestic Market Expansion – Increasing penetration in Tier 2 & Tier 3 cities through branded generics.
🔹Capacity Utilization Improvement – Optimizing existing plant operations to drive better efficiencies and cost reduction.
🔹Government Incentives – Jammu facility eligible for:
-GST-linked incentive (300% of investment in plant & machinery) for 10 years
-Capital interest subvention (6% reduction in loan interest costs)

📊Total Installed Capacity: 20+ billion dosage units annually across multiple plants
📊 Planned Expansion Impact: Higher production capacity, stronger API integration, lower costs, and increased export revenues

📌Strategic capacity expansion, R&D investment, increasing market reach, and government incentives will drive Innova Captab’s high-growth trajectory.

Fundamental Analysis (Long term)

18 Mar 2025 04:15

2 | Business Model - How Does Innova Captab Make Money?

💊 Pharmaceutical Manufacturing & CDMO - Core Offerings:
1️⃣ Contract Development & Manufacturing (CDMO) – Provides formulation, development, and manufacturing services for 190+ pharmaceutical companies, contributing 55% of revenue.
2️⃣ Domestic Branded Generics – Portfolio of 600+ products, distributed through 5,000+ distributors and 1.5 lakh+ pharmacies, contributing 18% of revenue.
3️⃣ International Branded Generics – Presence in 25+ countries, including regulated markets like Canada & UK, contributing 12% of revenue.
4️⃣ API & Specialty Formulations – Strengthened through Sharon Bio-Medicine, which contributes 15% of revenue and supports formulation & API manufacturing.

💊 Product Portfolio & Business Verticals:
🔹CDMO (Contract Development & Manufacturing):
1️⃣ Diverse Offerings – Tablets, capsules, dry syrups, injectables, and BFS (Blow-Fill-Seal) products.
2️⃣ Strong Customer Base – Serving 14 out of the top 15 Indian pharma companies.

🔹Domestic Branded Generics:
1️⃣ Large-Scale Market Presence – ₹169 Cr revenue in 9M FY25, growing at 18% YoY.
2️⃣ Strong Distribution Network – 1.5 lakh+ touchpoints via pharmacies, distributors, and stockists.

🔹International Business (25+ countries):
1️⃣ Growing Presence in Regulated Markets – Expanding in the UK & Canada.
2️⃣ Revenue Growth – ₹113 Cr in 9M FY25, growing at 17% YoY.

🔹API & Injectable Business:
1️⃣ API & Formulation Synergies – Sharon Bio-Medicine generated ₹141.9 Cr in 9M FY25.
2️⃣ Injectable Expansion – New Jammu facility adds Dry Powder Injectables, LVP (Large Volume Parenterals), and Respules.

📌 Innova Captab is leveraging its strong CDMO business, domestic expansion, and international market entry for high growth.

Fundamental Analysis (Long term)

18 Mar 2025 04:14

🏥 Innova Captab Ltd - A Detailed Analysis

- Innova Captab is a leading integrated pharmaceutical company with a strong presence in CDMO (Contract Development & Manufacturing), domestic branded generics, and international markets.
-With continuous capacity expansion, strong CDMO partnerships, and new product introductions, the company is positioned for robust future growth.

📌 Current Price: ₹787
📊 52-Week High / Low: ₹1,260 / ₹421
💰 Market Cap: ₹4,500 Cr

Fundamental Analysis (Long term)

18 Mar 2025 04:12

Companies Trading Near their 5 Year Average P/E: Unleashing Financial Freedom

1️⃣ Skipper Ltd.
2️⃣ Pricol Ltd.
3️⃣ Angel One Ltd
4️⃣ Sonata Software Ltd.
5️⃣ Sirca Paints Ltd
6️⃣Kaynes Tech Ltd
7️⃣ Ultra Marine Pigments Ltd.

This is not buy sell suggestion

Fundamental Analysis (Long term)

17 Mar 2025 07:11

PATANJALI FOODS Management Says Co has nothing to do with Patanjali Ayurved's insurance foray - CNBCTV18

Target 4% margins in Oil biz and 8-10% in FMCG

Home & Personal Care will grow 15% YoY in FY26

Will see margin expansion continue for Palm Oil Plantation biz

Fundamental Analysis (Long term)

16 Mar 2025 12:08

📌Insights into Mr. Amit Agarwal, Secretary, Dept. of Pharmaceuticals, Union Min. of Chemicals & Fertilizers interview to Businessline

💊India is poised to attract nearly ₹17,000 crore in R&D investments in the Pharma sector by the FY28, covering segments like Cancer research, Med Tech, lifestyle disease prevention, innovative medical devices, orphan drugs, anti-microbial resistance, stem cell and gene therapies & precision medicines.

💰Nearly ₹5,000 crore scheme for the Promotion of Research & Innovation in Pharma MedTech Sector (PRIP) likely to see the first disbursals.

👉This scheme, launched by the Dept. of Pharmaceuticals under the Ministry of Chemicals & Fertilizers, has a total financial outlay of ₹5,000 crore, of which ₹4,250 crore is earmarked specifically for accelerating R&D investments.

💠This scheme will infuse ₹17,000 crore of Additional investment in priority area anticipation launch of 30 New Products or Technologies by the end of FY28.

🔶The PRIP scheme is divided into components, with 1st Component, involving an outlay of ₹700 crore, already implemented.

➡️This component includes the establishment of Centres of Excellence in seven NIPERs located in Mohali, Ahmedabad, Hajipur, Hyderabad, Kolkata, Guwahati & Rae Bareli.

💉These institutes are engaged in diverse R&D activities such as anti-viral and anti-bacterial drug development, phyto-pharmaceuticals, continuous manufacturing, and novel drug discovery.

📌Component B of the scheme is categorized into three parts :

1⃣Category 1 targets established Indian pharmaceutical companies willing to collaborate with academia. It will fund nine projects, each with a maximum government support of ₹125 crore or 35% of the project cost, whichever is lower.

2⃣ Category 2 focuses on 30 projects aimed at bringing products to marketable stages, with each receiving up to ₹100 crore or 35% of the cost, whichever is lower.

3⃣Category 3 supports MSMEs, start-ups & research-driven companies, with funding of ₹1 crore each for approximately 125 projects over a five-year period.

📌Conclusion :

👉Nationwide road shows are also being planned to promote awareness & participation in this initiative.

➡️Overall, PRIP is a significant step towards bolstering India’s position in global pharmaceutical innovation & technological advancement.

Fundamental Analysis (Long term)

14 Mar 2025 12:29

/channel/AIXhashbot/AIXhash?startapp=329419785

Fundamental Analysis (Long term)

13 Mar 2025 09:16

Aeroflex Industries Ltd
Deep Industries Ltd
Dynacons Systems & Solutions Ltd
Ganesha Ecosphere Ltd
Gokul Agro Resources Ltd
J.G.Chemicals Ltd
Kernex Microsystems (India) Ltd
Kitex Garments Ltd
Kolte Patil Developers Ltd
TCPL Packaging Ltd
Skipper Ltd
Goldiam International Ltd
Pokarna Ltd
Premier Explosives Ltd
Moschip Technologies Ltd
Jagsonpal Pharmaceuticals Ltd
Supriya Lifescience Ltd
D.P. Abhushan Ltd
Krishana Phoschem Ltd

Fundamental Analysis (Long term)

13 Mar 2025 08:38

SOME Fundamental POINTS

1:If PE is higher than Return on equity with debt to equity more than 1 then such stocks are quite risky.

2:IF PE is lower than Return on equity with zero debt such companies far attractive.

Fundamental Analysis (Long term)

13 Mar 2025 08:19

Merger benefits will start coming in early FY26, margin expected in the range of 25% in the next 3- 5 years

Very confident about growth plans for co & promoters will not sale stake

Alisha Moopen, Aster DM Healthcare to CNBC-TV18

Fundamental Analysis (Long term)

13 Mar 2025 06:48

HAPPIEST MIND Management Says Maintain 30% Rev Growth Guidance For FY25, But Looking Tough To Achieve It - CNBCTV18

Fundamental Analysis (Long term)

18 Mar 2025 04:28

10 | Industry Outlook & Market Opportunity

🔹Global Pharma Market Growth:
✅ $1,635 Bn in 2023 → $2,251 Bn by 2028 (CAGR 6.6%) – Driven by rising healthcare spending & specialty generics.
✅ Regulated pharma markets expected to dominate with 77% share by 2028.

🔹CDMO Market Expansion:
✅ CDMO market growing at 7.7% CAGR – Outpacing the overall pharma industry.
✅ India emerging as a key CDMO hub – Competitive cost structure & skilled workforce.
✅ Strong demand from regulated markets – UK, Canada & Europe expanding CDMO partnerships.

🔹Emerging Market Growth:
✅ ₹376.3 Bn in 2023 → ₹541 Bn by 2028 (CAGR 7.5%) – Rising demand for branded generics in Africa, CIS, LATAM & SE Asia.
✅ Innova Captab’s international business scaling up – Presence in 25+ countries with expansion in regulated & emerging markets.

🔹Government & Regulatory Tailwinds Supporting Growth:
✅ PLI Scheme for bulk drugs & APIs – Incentivizing local manufacturing in India.
✅ GST & interest subvention for new plants – Jammu facility benefiting from 300% GST-linked incentives & 6% capital interest subvention.
✅ Regulatory push for localized manufacturing – Increased approvals & capacity expansion in key export markets.

📌Innova Captab is well-positioned to capitalize on the booming CDMO sector, rising demand for specialty generics, and increasing global pharma spending, backed by strong government incentives & international expansion.

Fundamental Analysis (Long term)

18 Mar 2025 04:24

9 | Valuation & Key Metrics

📢 Does It Pass Fundamental Investment Screening?

✅ Passes 5/9 Key Investment Filters
❌ Fails in P/E, ROE, ROCE & PB Ratio

(NO buy/Sell recommendation)

📊 Positives:
✅ Exceptional Profit Growth (53.7% YoY) – Strong earnings expansion.
✅ Strong Promoter Holding (50.9%) – Indicates management confidence.
✅ No Pledged Shares (0%) – Zero risk of share dilution.
✅ Growing CDMO & API Business – Expansion in Jammu facility & international markets driving future growth.
✅ Healthy Debt to Equity (0.29) – Well-managed leverage position.

⚠️ Concerns:
❌ High P/E (34.9) – Valuation premium compared to screening benchmark.
❌ ROE (17.0%) Below Ideal (20%) – Needs improvement in return on equity.
❌ ROCE (19.0%) Below Ideal (20%) – Marginally lower capital efficiency.
❌ High Price to Book Value (4.96) – Valuation slightly stretched.

📌 Innova Captab is not a textbook-perfect fundamental stock but a high-growth business with strong financials, profitability, and expansion potential. Investors should monitor valuation, efficiency improvements, and long-term CDMO execution.

Fundamental Analysis (Long term)

18 Mar 2025 04:19

7 | Financial Performance

📊 Quarterly Performance (Q3 FY25)
🔹Revenue: ₹316.5 Cr (⬆️ 4.6% YoY)
🔹EBITDA: ₹50.9 Cr (⬆️ 8.5% YoY)
🔹EBITDA Margin: 16.1% (⬆️ 60 bps)
🔹Profit Before Tax (PBT): ₹45.6 Cr (⬆️ 29.5% YoY)
🔹Profit After Tax (PAT): ₹34.2 Cr (⬆️ 36.3% YoY)
🔹PAT Margin: 10.8% (⬆️ 250 bps)
🔹Earnings Per Share (EPS): ₹5.97 (vs. ₹4.39 in Q3 FY24)

📈 Nine-Month Performance (9M FY25)
🔹Revenue: ₹928.9 Cr (⬆️ 13.5% YoY)
🔹EBITDA: ₹147.1 Cr (⬆️ 19% YoY)
🔹EBITDA Margin: 15.8% (⬆️ 80 bps)
🔹Profit Before Tax (PBT): ₹131.7 Cr (⬆️ 46.3% YoY)
🔹Profit After Tax (PAT): ₹98.7 Cr (⬆️ 50.5% YoY)
🔹PAT Margin: 10.6% (⬆️ 260 bps)
🔹Earnings Per Share (EPS): ₹17.25 (vs. ₹11.47 in 9M FY24)

💰 Financial Strength
🔹Healthy Balance Sheet – Strong profitability & efficient working capital management
🔹Strong Order Book – CDMO contracts & international expansion driving revenue visibility

📌 Innova Captab continues to showcase strong financial performance, driven by CDMO growth, strategic expansion, and improving profitability.

Must JOIN for such detail Analysis 👇
/channel/+Rn8RmYm0XMZTagXs

Fundamental Analysis (Long term)

18 Mar 2025 04:16

5 | Innova Captab Key Clients & Partnerships

♻️ Long-Term Partnerships Driving Growth
CDMO revenue remains a key growth driver, with a strong client base of 190+ pharmaceutical companies, including 14 of the top 15 Indian pharma players.

📊Top Clients & Contribution:
🔹Client Retention – 80%+ of clients have been associated for over five years.
🔹CDMO Product Portfolio – Manufacturing 2,900+ CDMO products across multiple dosage forms.

🏆 Key Clients (Leading Pharmaceutical Companies):
🔹Serving 14 of the top 15 pharmaceutical companies in India – Strong presence in CDMO & formulation partnerships.
🔹190+ CDMO clients – Includes major players in regulated & semi-regulated markets.
🔹80%+ of clients retained for over five years – Demonstrating long-term trust & recurring business.
🔹Strategic partnerships across formulations & APIs – Expanding into injectables, LVP, and respules with the new Jammu facility.
🔹Growing CDMO collaborations in regulated markets – Increasing filings & approvals to strengthen presence in UK & Canada.

🚀 Expanding CDMO & International Partnerships:
🔹Increased filings & approvals to boost presence in UK & Canada.
🔹Product portfolio expansion into injectables, LVP, and respules with new Jammu facility.
🔹Deepening presence in Tier 2 & 3 cities for domestic branded generics.

🏛 Government & Institutional Collaborations:
🔹Eligible for government incentives in Jammu, supporting long-term cost advantages.
🔹Supplying essential medicines & critical care injectables to government hospitals & institutions.
🔹Benefiting from PLI scheme & GST-linked incentives, enhancing financial position.

📌Innova Captab’s strong client base, long-term contracts, and CDMO expansion position it as a leading player in the Indian and global pharmaceutical markets.

Fundamental Analysis (Long term)

18 Mar 2025 04:15

3 | Revenue Model & Contribution

🔹Revenue Model:
1️⃣ CDMO Services – Contract development & manufacturing for 190+ pharmaceutical companies, including 14 of the top 15 Indian pharma players.
2️⃣ Branded Generics Sales – Direct distribution to 5,000+ distributors and 1.5 lakh+ pharmacies in India.
3️⃣ International Business – Supplying formulations to 25+ countries, including regulated markets like the UK & Canada.

🔹Revenue Contribution (By Business Segment, 9M FY25):
1️⃣ CDMO Business – 55% (₹505.1 Cr).
2️⃣ Domestic Branded Generics – 18% (₹169 Cr).
3️⃣ International Branded Generics – 12% (₹113 Cr).
4️⃣ API & Formulations (Sharon Bio-Medicine) – 15% (₹141.9 Cr).

🔹Core Raw Materials Used:
1️⃣ Active Pharmaceutical Ingredients (APIs) – Sourced externally and through Sharon Bio-Medicine for cost efficiency.
2️⃣ Excipients & Formulation Components – Used in oral solids, dry syrups, injectables, and BFS products.
3️⃣ Packaging Materials – Vials, bottles, blister packs, and sterile containers for diverse formulations.

📌 Innova Captab’s well-diversified revenue model, strong CDMO partnerships, and increasing international presence ensure sustained growth and market leadership.

Fundamental Analysis (Long term)

18 Mar 2025 04:15

1 | Who is Innova Captab?

📍Company Overview:
🔹Founded: 2006
🔹Headquarters: Baddi, Himachal Pradesh, India
🔹Business Model: Integrated pharmaceutical company with a strong presence in CDMO (Contract Development & Manufacturing), domestic branded generics, and international markets.
🔹Presence: Serving 14 out of the top 15 pharmaceutical companies in India, exporting to 25+ countries, including regulated markets like the UK & Canada.
🔹Manufacturing Plants: 9 production blocks across multiple locations, including the newly commercialized Jammu facility.
🔹Total Installed Capacity:
-Baddi Plant: Tablets (8.2B), Capsules (2.4B), Dry Powder Injectables (60M).
-Jammu Plant: Tablets (10.6B), Capsules (1.4B), BFS Injectables (562M).
-Sharon Bio-Medicine (API & Formulations): Tablets & Capsules (2B), API Production (313 MT).
🔹Market Position: Among the top 3 largest finished tablet and capsule manufacturers in India.

🏢 Subsidiaries & Business Divisions:
🔹Sharon Bio-Medicine Ltd - API & Formulations manufacturing, supporting backward integration and catering to international markets (Canada, UK, Europe, Australia, Korea, Vietnam).
🔹Univentis Medicare Ltd - Marketing & distribution arm for the domestic branded generics segment.

📌 With its strategic capacity expansion, new product introductions, and strong CDMO & generics presence, Innova Captab is well-positioned for continued growth.

Fundamental Analysis (Long term)

18 Mar 2025 04:14

INNOVA CAPTAB DETAIL ANALYSIS

Fundamental Analysis (Long term)

17 Mar 2025 07:27

KEC INTERNATIONAL says

• Power Grid accounts for 20-25% of our order book

• Power Grid contributes 30-35% of our order intake

• Exported $25 million worth of products from Mexico to the US

• No impact of US tariffs on KEC International

• No plans to set up manufacturing plants in the US at the moment

• Targeting 15% growth in FY26

Fundamental Analysis (Long term)

17 Mar 2025 02:21

Short term trading , positional trading
And learning priceaction join now @wealthcreator7

Stock SIP, long term investment don't miss to join @stocksip

Corporate update, quaterely result, management guidance @companyupdate

Daily one company Fundamental analaysis in detail daily
@fundamental3

US STOCK Chart study for more detail visit
@Us_stock3

Order Book, capex and stock information in detail @stockinfo33

Stock market statics and information @stockinfo3

All IPO Updates Live @ipoinfo3

All conference call and detail stock study @nilfaldu

Fundamental Analysis (Long term)

15 Mar 2025 05:09

Good Morning friends

Fundamental Analysis (Long term)

14 Mar 2025 08:34

Innova Captab - Centrum CDMO Conference Key Takeaways :

🔹FY25 revenue target: ₹12bn+
🔹Jammu plant to add ₹4-5bn revenue by FY26
🔹20%+ CAGR expected over next 3-5 yrs

Jammu Plant Key Highlights:
🔹₹4.5bn investment for new facility
🔹4 blocks: Cephalosporin, Penicillin, Pennum & General
🔹Commercial production starts Q4FY25
🔹Expected breakeven in H1FY26

Financial Benefits:
🔹Interest Subsidy: Govt-backed loan at ~2.5% effective rate
🔹GST Incentive: ₹3bn benefit (3x eligible investment)
🔹To unlock full GST benefit, sales need to hit ₹7.5bn/yr from Jammu

CDMO & API Trends:
🔹CDMO Model: In-house product development, customer validation, & contract manufacturing
🔹API cost model: Price hikes passed on to customers
🔹API price trend: Volatile, 4-5% decline impacting margins

Trade Generics & Market Outlook:
🔹Trade generics growth: 15% CAGR (current market ~₹2bn+)
🔹White-labeled pharmacy generics eating into branded generics
🔹More outsourcing to CDMOs due to stricter regulations

Market Positioning & Growth Factors:
🔹Increased outsourcing benefits large CDMOs
🔹Domestic branded generics field force: 300-350 reps
🔹Regulatory shifts (e.g., Schedule M implementation) to favor bigger CDMOs

Big growth ahead for Innova Captab

Source : Centrum
(No Buy/Sell reco)

Fundamental Analysis (Long term)

13 Mar 2025 09:01

💎Quarterly Growers

💎19 Small Cap Companies showing Consistent Quarterly growth in Net Profit

🔼Q3FY25 PAT > Q2FY25 PAT
🔼Q2FY25 PAT > Q1FY25 PAT
🔼Q1FY25 PAT > Q4FY24 PAT

Fundamental Analysis (Long term)

13 Mar 2025 08:25

JK Lakshmi Cement says
💪 Demand is good, hope that prices will trend up
👍 Cement Prices +1% -1.5% in Q4FY25 vs Q3FY25

FY26 Guidance
🎯 Volumes +9% yoy
🎯 EBITDA/tn improves Rs.200/tn

Fundamental Analysis (Long term)

13 Mar 2025 06:48

HAPPIEST MIND Management Says We Are Coming To Speed With The Rhythm Of The Product Biz

Upbeat About Outlook But Coloured Slightly By Fear Of A Recession In US

We Are Currently In The Planning Phase For Renewals

Customers Watching How The Situation Is Evolving, No Cut On Spending So Far

Renewal Cycle That Started In December Is Almost Through

Fundamental Analysis (Long term)

12 Mar 2025 20:05

Short term trading , positional trading
And learning priceaction join now @wealthcreator7

Stock SIP, long term investment don't miss to join @stocksip

Corporate update, quaterely result, management guidance @companyupdate

Daily one company Fundamental analaysis in detail daily
@fundamental3

US STOCK Chart study for more detail visit
@Us_stock3

Order Book, capex and stock information in detail @stockinfo33

Stock market statics and information @stockinfo3

All IPO Updates Live @ipoinfo3

All conference call and detail stock study @nilfaldu